BIOPHYTIS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 EUR | 0.00% |
|
+1.19% | -58.33% |
| May. 14 | Biophytis unveils design for obesity study | CF |
| May. 14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
| Sales 2024 * | - | Sales 2025 * | 4.8M 5.19M | Capitalization | 2.17M 2.35M |
|---|---|---|---|---|---|
| Net income 2024 * | -19M -20.55M | Net income 2025 * | -16M -17.31M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.45 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.58% |
More Fundamentals
* Assessed data
Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19.
The company is located in Paris, France and Cambridge, Massachusetts.
Calendar
2024-10-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +11.03% | 115B | |
| +12.60% | 106B | |
| -4.23% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.15% | 17.56B | |
| -40.50% | 17.32B | |
| +6.43% | 14.03B | |
| +31.62% | 12.13B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock
